Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2003-06-06
2011-11-01
Audet, Maury (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S001100, C514S005400, C514S018900, C514S019200, C514S019300, C549S349000, C530S300000, C424S001690
Reexamination Certificate
active
08048850
ABSTRACT:
In one aspect, the invention provides covalent conjugates between artemisinin-related endoperoxides and iron-carrying proteins. In some embodiments, the covalent conjugates comprise artelinate and holotransferrin. In another aspect, the invention provides methods for administering the covalent conjugates of the invention to treat cancer and infections by pathogens that bind iron-carrying proteins.
REFERENCES:
patent: 4698387 (1987-10-01), Schmidt
patent: 5216175 (1993-06-01), Avery et al.
patent: 5578637 (1996-11-01), Lai et al.
patent: 6054133 (2000-04-01), Horwitz et al.
patent: 6127405 (2000-10-01), Kumar
patent: 6160004 (2000-12-01), Posner
patent: 6214864 (2001-04-01), Jain et al.
patent: 6297272 (2001-10-01), Posner et al.
patent: 6307068 (2001-10-01), Li
patent: 6486199 (2002-11-01), Vennerstrom et al.
patent: 6906205 (2005-06-01), Vennerstrom et al.
patent: 7692030 (2010-04-01), Sasaki et al.
patent: 2003/0108556 (2003-06-01), Mekalanos et al.
patent: 2005/0256185 (2005-11-01), Vennerstrom et al.
patent: 85/00812 (1985-02-01), None
patent: 96/34602 (1996-11-01), None
patent: 97/01548 (1997-01-01), None
patent: 00/42046 (2000-07-01), None
patent: 01/04123 (2001-01-01), None
patent: 02/091992 (2002-11-01), None
Payne. Exploiting intracellular iron and iron-rich compounds to effect tumor cell lysis. (Medical Hypothesis; vol. 61, Issue 2, Aug. 2003, pp. 206-209. (Copy not included as not prior art, but available via PubMed].
Cornelissen, C.N., “Transferrin-Iron Uptake by Gram-Negative Bacteria,”Frontiers in Bioscience 8:d836-847, May 1, 2003.
Cumming, J.N., et al., “Design, Synthesis, Derivatization, and Structure-Activity Relationships of Simplified, Tricyclic, 1,2,4-Trioxane Alcohol Analogues of the Antimalarial Artemisinin,”J. Med. Chem. 41:952-964, 1998.
Efferth, T., et al., “The Anti-Malarial Artesunate Is Also Active Against Cancer,”International Journal of Oncology 18:767-773, 2001.
Efferth, T., et al., “mRNA Expression Profiles for the Response of Human Tumor Cell Lines to the Antimalarial Drugs Artesunate, Arteether, and Artemether,”Biochemical Pharmacology 64:617-623, 2002.
Efferth, T., et al., “Activity of Drugs From Traditional Chinese Medicine Toward Sensitive and MDR1- or MRP1-Overexpressing Multidrug-Resistant Human CCRF-CEM Leukemia Cells,”Blood Cells, Molecules, and Diseases 28(2):160-168, Mar./Apr. 2002.
Evans, R. W., and J.S. Oakhill, “Transferrin-Mediated Iron Acquisition by PathogenicNeisseria,” Biochem. Soc. Trans. 30(4):705-707, Aug. 2002.
Gray-Owen, S.D., and A.B. Schryvers, “Bacterial Transferrin and Lactoferrin Receptors,”Trends in Microbiology 4(5):185-191, May 1996.
Lai, H., and N.P. Singh, “Selective Cancer Cell Cytotoxicity From Exposure to Dihydroartemisinin and Holotransferrin,”Cancer Letters 91:41-46, 1995.
Li, Y., et al., “Novel Antitumor Artemisinin Derivatives Targeting G1 Phase of the Cell Cycle,”Bioorganic&Medicinal Chemistry Letters 11:5-8, 2001.
Moore, J.C., et al., “Oral Administration of Dihydroartemisinin and Ferrous Sulfate Retarded Implanted Fibrosarcoma Growth in the Rat,”Cancer Letters 98:83-87, 1995.
Sadava, D., et al., “Transferrin Overcomes Drug Resistance to Artemisinin in Human Small-Cell Lung Carcinoma Cells,”Cancer Letters 179:151-156, 2002.
Sing, N.P., and H. Lai, “Selective Toxicity of Dihydroartemisinin and Holotransferrin Toward Human Breast Cancer Cells,”Life Sciences 70:49-56, 2001.
Singh, N.P., and K.B. Verma, “Case Report of a Laryngeal Squamous Cell Carcinoma Treated With Artesunate,”Archive of Oncology 10(4):249-280, 2002.
Wandersman, C., and I. Stojiljkovic, “Bacterial Heme Sources: the Role of Heme, Hemoprotein Receptors and Hemophores,”Curr. Opin. Microbiol. 3(2):215-220, Apr. 2000.
Anfosso, L., et al., “Microarray Expression Profiles of Angiogenesis-Related Genes Predict Tumor Cell Response to Artemisinins,”The Pharmacogenomics Journal, 2006, pp. 1-10.
Avery, M.A., et al., Simplified Analogues of the Antimalarial Artemisinin: Synthesis of 6,9-Desmethylartemisinin,J. Org. Chem. 54:1792-1795, 1989.
Avery, M.A., et al., “Total synthesis of (+)-Artemisinin and (+)-9-Demethylartemisinin,”Tetrahedron Letters 28:4629-4632, 1987.
Benoit-Vical, F., et al., “In Vitro and In Vivo Potentiation of Artemisinin and Synthetic Endoperoxide Antimalarial Drugs by Metalloporphyrins,”Antimicrobial Agents and Chemotherapy 44(10):2836-2841, Oct. 2000.
Bez, G., et al., “Recent Developments With 1,2,4-Trioxane-Type Artemisinin Analogues,”Current Organic Chemistry 7:1231-1255, 2003.
Gu, H.M., et al., “Antimalarial Activities of 25 Derivatives of Artemisinine Against Chloroquine-ResistantPlasmodium berghei,” Acta Pharmacol. Sinica 1(1):48-50, 1980. (Abstract only).
Imakura, Y., et al., “Acid Degradation Products of Qinghaosu and Their Structure-Activity Relationships,”Heterocycles 31(6):1011-1016, Jun. 1, 1990. (Abstract only).
Imakura, Y., et al., “Synthesis of Desethanoqinghaosu, a Novel Analogue of the Antimalarial Qinghaosu,”J. Chem. Soc. Chem. Comm., 1988, pp. 372-374.
Lin, A.J., et al., “Antimalarial Activity of New Water-Soluble Dihydroartemisinin Derivatives. 2. Stereospecificity of the Ether Side Chain,”J. Med. Chem. 32(6):1249-1252, Jun. 1989. (Abstract only).
Peters, W., et al., “The Chemotherapy of Rodent Malaria. XLIX. The activities of Some Synthetic 1,2,4-Trioxanes Against Chloroquine-Sensitive and Chloroquine-Resistant Parasites. Part 2: Structure-Activity Studies oncis-Fused Cyclopenteno-1,2,4-Trioxanes (Fenozans) Against Drug-Sensitive and Drug-Resistant Liens ofPlasmodium bergheiandP. yoeliissp. NS In Vivo,”Ann. Trop. Med. Parasit. 87(1):9-16, 1993.
Posner, et al., “Extraordinarily Potent Antimalarial Compounds: New, Structurally Simple, Easily Synthesized, Tricyclic 1,2,4-Trioxanes,”J. Med. Chem. 35:2495-2467, 1992.
Vennerstrom, J.L., and J.W. Eaton, “Oxidants, Oxidant Drugs, and Malaria,”Journal of Medicinal Chemistry 31(7):1269-1277, Jul. 1988.
Vennerstrom, J.L., et al., “Dispiro-1,2,4,5-Tetraoxanes: A New Class of Antimalarial Peroxides,”Journal of Medicinal Chemistry 35:3023-3027, 1992.
Vennerstrom, J.L., et al., “Identification of an Antimalarial Synthetic Trioxolane Drug Development Candidate,”Nature 430:900-904, Aug. 2004.
Zaman, S.S., and R.P. Sharma,“Some Aspects of the Chemistry and Biological Activity of Artemisinin and Related Antimalarials,”Heterocycles 32:1593-1638, 1991.
Ferreira, J.F.S., and J. Janick, “Immunoquantitative Analysis of Artemisinin From Artemisia Annua Using Polyclonal Antibodies,” Phytochemisty 41(1):97-104, 1996.
Zheng, G.Q., “Cytotoxic Terpenoids and Flavonoids From Artemisia Annua,” Planta Med. 60(1):54-57, 1994 (abstract only).
H. Lai, et al., “Targeted Treatment of Cancer With Artemisinin and Artemisinin-Tagged Iron-Carrying Compounds,” Expert Opin. Ther. Targets 9(5):995-1007, 2005.
Shoeb, H.A., “Antimicrobial Activity of Artemisinin and its Derivatives Against Anaerobic Bacteria,” <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&List—uids...> [retrieved Sep. 1, 2006].
Surolia, N., and S. Misquith, “Cell Surface Receptor Directed Targeting of Toxin to Human Malaria Parasite,Plasmodium falciparum,” FEBS [Federation of European Biochemical Societies] Letters 396(1):57-61, Oct. 28, 1996.
Woerdenbag, H. J., et al., “Cytotoxicity of Artemisinin-Related Endoperoxides to Ehrlich Ascites Tumor Cells,” Journal of Natural Products 56(6):849-856, Jun. 1993.
Beekman, A.C., et al., “Stability of Artemisinin in Aqueous Environments: Impact on Its Cytotoxic Action to Ehrlich Ascites Tumour Cells,” Journal of Pharmacy and Pharmacology 4
Lai Henry C.
Sasaki Tomikazu
Singh Narendra P.
Audet Maury
Christensen O'Connor Johnson & Kindness PLLC
University of Washington
LandOfFree
Covalent conjugates between artemisinin-related... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Covalent conjugates between artemisinin-related..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Covalent conjugates between artemisinin-related... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4272305